HOLOGIC INC. overview

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 29, 2025 . “We delivered on our financial commitments in the second quarter,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share buybacks and a slightly lower tax rate.”...

Hologic, Inc. (Nasdaq: HOLX) will have a strong presence at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs, Colorado this week, including the presentation of pivotal new research conducted by a top-tier healthcare facility focused on the company’s AI-driven mammography technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424821675/en/ Groundbreaking New Data on Hologic’s AI-Powered Mammography...

Hologic, Inc. (Nasdaq: HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its annual sustainability report with an emphasis on expanded environmental commitments and efforts to advance access and equity in women’s health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422781805/en/ Hologic 2024 Sustainability Report For...

Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250404530519/en/ Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET). The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following each event. About Hologic Hologic, Inc. is an innovative medical technology company...

Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm ® Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures, 1-2 is now CE-marked. The technology received clearance from the U.S. Food and Drug Administration in October 2020. Designed from the ground up to integrate with the Selenia ® Dimensions ® and 3Dimensions™ systems,...

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020. “Our COVID test was instrumental in addressing critical testing needs during the pandemic and offered healthcare providers and laboratories a solution that was highly sensitive and able to help mitigate outbreaks. Nearly five years after the...